Ignite Creation Date:
2024-05-06 @ 12:28 PM
Last Modification Date:
2024-10-26 @ 12:59 PM
Study NCT ID:
NCT03761914
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2022-02-21
First Post:
2018-11-28
Brief Title:
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sponsor:
Sellas Life Sciences Group
Organization:
Sellas Life Sciences Group
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Small-cell Lung Cancer |
| Acute Myelogenous Leukemia |
| Ovarian Cancer |
| Colorectal Cancer |
| Triple-negative Breast Cancer |
Keywords:
| Name | View |
|---|---|
| WT1 analog peptide vaccine | View |
| peptide vaccine | View |
| immuno-oncology | View |
| WT1-expressing tumors | View |
| galinpepimut-S | View |
| pembrolizumab | View |
| PD1 inhibitor | View |
| checkpoint inhibitor | View |
| combination immunotherapy | View |
| heteroclitic | View |
| multivalent | View |
| off-the-shelf vaccine | View |
| HLA allele | View |
| WT1 vaccine | View |
| SLS-001 | View |